Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

Earnings Preview: What to Expect From Eli Lilly's Report

Earnings Preview: What to Expect From Eli Lilly's Report

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says

This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Rocket Lab Corporation (NASDAQ:RKLB) is a buy, adding that it is “one of the hottest stocks in the universe.”

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

Are Growth Stocks Back? 3 That Look Like Winners to Buy Now

Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…

inkl

Read news from The Economist, FT, and more,
with one subscription

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

The Independent UK

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Is Eli Lilly and Company Stock Underperforming the Dow?

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

5 High-Potential Stocks That Could Have Your Investments Rising Quickly

The stock market doesn’t hand out guarantees. But every so often, a few companies show signs of powerful upward movement due to innovation, market shifts,...

The Conversation

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?

This week, Australia’s Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer’s disease.

The Guardian - AU

Australia approves new drug to treat early Alzheimer’s disease

Kisunla is first new treatment registered by TGA in 25 years but could cost patients more than $80,000 and less than one in five will be eligible

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

The Guardian - UK

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

1 … 11 12 13 14

People

176,556 stories

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Executive Order

Alzheimer Disease

Places

355,577 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play